Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Saudi J Gastroenterol. 2023 Jul-Aug;29(4):212-218. doi: 10.4103/sjg.sjg_503_22.
As the population ages, the number of elderly inflammatory bowel disease (IBD) patients is expected to increase. The clinical features and therapeutic options for young and old patients may differ, as elderly IBD patients are likely to have different comorbidities and disease characteristics. The goal of this study was to examine the clinical aspects and therapeutic choices for elderly Saudi IBD patients.
We conducted a retrospective study aimed at describing the demographic, clinical, and management characteristics of IBD in elderly patients (≥60 years) who followed up at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. The data was extracted from the KAUH inflammatory bowel disease information system (IBDIS) registry. The primary outcome was to describe disease characteristics in accordance with the Montréal classification and the secondary outcomes were to describe treatment patterns and identify significant clinical associations.
Our data were collected from 76 patients who fulfilled the study inclusion criteria. Females outnumbered males (53.9% vs 46.1%) and the mean age was 51.5 ± 9.7 years. Essential hypertension (26.3%) was the most common comorbidity followed by diabetes mellitus (23.6%), and malignant neoplasms (9.21%). More than half of the patients with Crohn's disease (CD) had disease onset after forty years of age. The most common form of disease distribution was ileocolonic disease (64.7%). Less than 17% of patients had a penetrating disease phenotype. About 88 percent of patients with UC presented >40 years of age. Approximately, half of the cohort had left-sided ulcerative colitis (UC) (48%), followed by pancolitis (40%). The most prescribed medication class for IBD was 5-aminosalicylic acid (5-ASA) derivatives (56.58%) followed by corticosteroids and immunosuppressive drugs.
In Saudi Arabia, age-specific concerns including comorbidities and polypharmacy remain the major challenges in the management of elderly IBD patients.
随着人口老龄化，老年炎症性肠病（IBD）患者的数量预计将会增加。年轻和老年患者的临床特征和治疗选择可能不同，因为老年 IBD 患者可能具有不同的合并症和疾病特征。本研究的目的是研究沙特老年 IBD 患者的临床方面和治疗选择。
我们进行了一项回顾性研究，旨在描述在沙特阿拉伯吉达的阿卜杜勒阿齐兹国王大学医院（KAUH）就诊的老年（≥60 岁）IBD 患者的人口统计学、临床和管理特征。该数据是从 KAUH 炎症性肠病信息系统（IBDIS）登记处提取的。主要结局是根据蒙特利尔分类描述疾病特征，次要结局是描述治疗模式并确定有意义的临床关联。
我们的数据来自 76 名符合研究纳入标准的患者。女性多于男性（53.9%比 46.1%），平均年龄为 51.5±9.7 岁。最常见的合并症是原发性高血压（26.3%），其次是糖尿病（23.6%）和恶性肿瘤（9.21%）。超过一半的克罗恩病（CD）患者在 40 岁后发病。最常见的疾病分布形式是回结肠疾病（64.7%）。不到 17%的 UC 患者具有穿透性疾病表型。大约 88%的 UC 患者发病年龄大于 40 岁。大约一半的患者患有左侧溃疡性结肠炎（UC）（48%），其次是全结肠炎（40%）。IBD 最常开的药物类别是 5-氨基水杨酸（5-ASA）衍生物（56.58%），其次是皮质类固醇和免疫抑制剂。
在沙特阿拉伯，年龄相关的问题，包括合并症和多药物治疗，仍然是老年 IBD 患者管理的主要挑战。
